Description

Triductan MV (trimetazidine) Coated Tablets with Prolonged Release 35 mg. №60

Ingredients

Active ingredient: Trimetazidine 35 mg.
Other ingredients: lactose monohydrate, hypromellose, colloidal anhydrous silica, magnesium stearate, macrogol, talc.

Dosage

Recommended dosage: 1 tablet daily, swallowed whole with water, preferably during meals.

Indications

Triductan MV (trimetazidine) is indicated for:

• Improving myocardial glucose utilization
• Preventing or relieving angina pectoris
• Supporting cardiac function in coronary artery disease

Contraindications

Do not use Triductan MV if you:

• Are allergic to trimetazidine or any other ingredients
• Have severe renal impairment
• Are pregnant or breastfeeding

Directions

Follow these directions while using Triductan MV:

• Consult your doctor for the appropriate dosage
• Do not exceed the recommended dose
• Inform your doctor about any other medications you are taking

Scientific Evidence

Trimetazidine’s efficacy in improving cardiac function has been extensively studied. Research by Kantor et al. (2009) demonstrated that trimetazidine significantly increased left ventricular ejection fraction in patients with heart failure. Additionally, a meta-analysis by Fragasso et al. (2016) concluded that trimetazidine reduced angina episodes and improved exercise tolerance in patients with stable angina.

Additional Information

Pharmacological Effects: Trimetazidine acts by shifting myocardial substrate utilization from fatty acids towards glucose, thereby preserving energy metabolism and improving cardiac efficiency. This mechanism helps in reducing ischemia-related symptoms and supporting cardiac function.

Clinical Trials: Clinical trials have shown that trimetazidine, such as in Triductan MV, is well-tolerated and effective in improving symptoms of angina and heart failure. Comparative studies have indicated its comparable efficacy to other anti-anginal agents with the added benefit of metabolic modulation.